April 2021 in “Journal of Investigative Dermatology” The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.
January 2021 in “International Journal of Research in Medical Sciences” During the COVID-19 lockdown, there were fewer cases of mild skin issues and more cases of stress-related skin conditions.
December 2020 in “Research Square (Research Square)” The AndroCoV Clinical Scoring is a quick, affordable, and accurate method for diagnosing COVID-19.
October 2022 in “Journal of health sciences and medicine” Middle-aged and elderly men with BPH had higher hospitalization rates for COVID-19.
2 citations,
October 2020 in “Journal of Pharmacy And Bioallied Sciences” Hydroxychloroquine and chloroquine are not recommended for COVID-19 treatment due to insufficient evidence and safety concerns.
125 citations,
August 2020 in “Frontiers in Immunology” Men generally have more severe COVID-19 cases and higher death rates than women due to biological differences.
51 citations,
August 2021 in “Turkish Journal of Medical Sciences” As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.
49 citations,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
49 citations,
May 2020 in “Frontiers in Public Health” Insulin resistance linked to obesity may increase COVID-19 severity.
42 citations,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
42 citations,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
40 citations,
October 2020 in “Diabetes and Metabolic Syndrome: Clinical Research and Reviews” Higher androgen levels might make COVID-19 worse, especially in men.
36 citations,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
27 citations,
December 2020 in “Experimental Dermatology” Grey hair and baldness may be linked to COVID-19 severity, but more analysis is needed; post-infectious hair loss is related to the severity of the disease and usually recovers within 3-6 months.
26 citations,
September 2020 in “Journal of the European Academy of Dermatology and Venereology” A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
21 citations,
January 2021 in “Therapeutic Advances in Endocrinology and Metabolism” Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.
19 citations,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
11 citations,
May 2021 in “Journal of Medical Virology” Men are more likely to have severe respiratory viral infections like COVID-19 due to hormonal and genetic differences, while women generally have stronger immune responses.
7 citations,
May 2022 in “Skin health and disease” Certain types of rashes in COVID-19 patients may indicate more severe illness and higher risk of death.
7 citations,
December 2020 in “Clinics in Dermatology” Some alopecia treatments might help treat COVID-19, but more research is needed.
6 citations,
December 2022 in “Journal of Infection” The ACE1 gene variant doesn't affect long-COVID symptoms.
6 citations,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
6 citations,
May 2021 in “Clinical Chemistry and Laboratory Medicine” Different ACE2 gene versions may affect COVID-19 impact based on age and suggest some hair loss drugs could be potential treatments.
5 citations,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
5 citations,
May 2021 in “International Journal of Infectious Diseases” A man experienced hair loss after getting COVID-19, which improved with treatment and might have been triggered by stress related to the illness.
5 citations,
November 2020 in “medRxiv (Cold Spring Harbor Laboratory)” 5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
4 citations,
June 2022 in “BioMed Research International” Using mesenchymal stem cells or their exosomes is safe for COVID-19 patients and helps improve lung healing and oxygen levels.
4 citations,
March 2022 in “Journal of Infection” Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.
4 citations,
May 2021 in “Journal of The European Academy of Dermatology and Venereology” Hair loss doesn't affect COVID-19 severity.
2 citations,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.